Navigation Links
Osteoporosis drug may help treat advanced hormone-sensitive breast cancer
Date:6/17/2013

A new osteoporosis drug hinders the growth of estrogen-sensitive cancer that has become resistant to treatment with tamoxifen, a study in mice shows. The results will be presented Saturday at The Endocrine Society's 95th Annual Meeting in San Francisco.

The medication, bazedoxifene, which is approved in Europe under the brand name Conbriza for the treatment and prevention of postmenopausal osteoporosis, also reduced estrogen activity and estrogen receptor levels in cultured human breast cancer cells, the study authors reported.

"Bazedoxifene, a known, safe drug approved in Europe, may present a near-term option as an effective therapy for breast cancer in patients who have relapsed during treatment with tamoxifen or aromatase inhibitors," said Suzanne Wardell, PhD, the study's principal investigator and a research scientist at Duke University, Durham, N.C.

About 70 percent of breast cancers are hormone sensitive, the National Cancer Institute estimates, meaning they need female hormones like estrogen to grow. In one-third to one-half of these patients, the cancer becomes resistant to medications that block either estrogen production or activity of the estrogen receptor, according to Wardell, who said, "These women then have few treatment options."

Treatment options include systemic, or whole-body, chemotherapy or often-painful injections of an anti-estrogen drug, fulvestrant into the buttocks muscle.

The investigators reasoned that one or more drugs known as selective estrogen receptor modulators, or SERMs, might prove effective in treating breast tumors that have developed resistance to hormone blockers. Most SERMs have anti-estrogen effects on some tissues and estrogen-like effects on other tissues. The new SERM bazedoxifene stimulates the estrogen receptor in bone to retain bone mineral density but inhibits estrogen receptor activation in the breast and uterus, Wardell said.

Wardell's team tested bazedoxifene in a study funded by the drug's manufacturer, Pfizer. First, they applied standard molecular biology techniques to multiple models of human-derived breast cancer cell lines. The models included cancer cells that were resistant to tamoxifen, aromatase inhibitors and lapatinib, a drug used to treat aggressive HER2-positive breast cancer. In all models, bazedoxifene reportedly inhibited estrogen-induced gene expression and cell proliferation.

The researchers then transplanted the cultured breast tumors into immune-compromised mice. Wardell said that bazedoxifene "completely inhibited the estrogen receptor-dependent tumor growth," not only in tumors that had never received tamoxifen treatment but also in those that were resistant to tamoxifen. The drug deterred tumor growth to a similar extent as reported for fulvestrant, she said.

The ideal next research step, according to Wardell, would be a clinical trial to evaluate the efficacy of bazedoxifene in patients with metastatic, hormone therapy-resistant breast cancer.

Pfizer has applied for U.S. Food and Drug Administration approval of bazedoxifene but only when combined with conjugated estrogens for treatment of postmenopausal symptoms and prevention of postmenopausal osteoporosis, she said.


'/>"/>

Contact: Aaron Lohr
alohr@endocrine.org
240-482-1380
The Endocrine Society
Source:Eurekalert

Related medicine news :

1. Simple Ways to Protect Yourself from the Risks of Osteoporosis
2. Nearly 30 percent of women fail to pick up new prescriptions for osteoporosis, study finds
3. Osteoporosis costs EU countries €37 billion every year
4. New scorecard shows inequalities in osteoporosis care in the Europe Union
5. Registration opens for Asia-Pacifics largest medical conference on osteoporosis
6. Smoking and depressive symptoms in adolescent girls are red flag for postmenopausal osteoporosis
7. Are there racial disparities in osteoporosis screening and treatment?
8. Teen smoking decreases bone accumulation in girls, may increase osteoporosis risk
9. Men with belly fat at risk for osteoporosis
10. Men May Benefit From Osteoporosis Drug, Too: Study
11. Has osteoporosis treatment failed when a fracture occurs?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... ... and Android devices. VisualDx is the first point of care diagnostic support ... general medicine. The system speeds diagnosis, therapy decisions and patient education for ...
(Date:5/5/2016)... ... ... is just around the corner. Summer means a lot of different things to people. ... all day and night. Parents often lament the coming of summer as they will have ... trips to the beach, backyard cookouts, fireworks on the Fourth of July, and even perhaps ...
(Date:5/5/2016)... ... , ... Dermatologic surgeons performed nearly 10 million medically necessary and cosmetic procedures ... , The results of the 2015 ASDS Survey on Dermatologic Procedures released today reveal ... the growing popularity of soft-tissue fillers and body sculpting procedures. , For the ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... , The Medical Society of Northern Virginia, Announces DoctorsTelemed?, A telehealth ... Medical Society of Northern Virginia (MSNVA) launches DoctorsTelemed?, a telemedicine solution that ...
(Date:5/5/2016)... , ... May 05, 2016 , ... Nepenthe Laboratory Services ... Elementary School last week to raise non-perishable food item donations for Food for Lane ... Day” hosted on NBC. , “The goal of the assembly was to create an ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... May 4, 2016  It,s time for an upgrade. There are many medical recorders ... 3.5 inch LCD, the illustrious DVMAXX HD  offers unparalleled connectivity and functionality.  Ampronix ... a world class manufacturer of innovative technology.  Photo - http://photos.prnewswire.com/prnh/20160503/363416 ... ... ...
(Date:5/4/2016)... New Jersey , May 4, 2016 ... its successful completion of an alternative public offering (APO). ... wholly owned operating company, Valeritas, Inc. and a private ... common stock at $5.00 per share. Under ... on May 3, 2016, Valeritas Holdings, Inc. will trade ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Acute lymphocytic Leukemia Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Leukemia Market and Competitive Landscape Highlights 2016, ... pipeline products, Acute Lymphocytic Leukemia epidemiology, Acute ...
Breaking Medicine Technology: